Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C28H29N3O8S
|
| gptkbp:clinicalTrials |
Phase III
NCT01321743 NCT02236000 NCT02299999 |
| gptkbp:contraindication |
anemia
liver disease pregnancy breastfeeding thrombocytopenia hepatotoxicity neutropenia cardiac toxicity |
| gptkbp:developedBy |
gptkb:Puma_Biotechnology
|
| gptkbp:drugInterdiction |
bioavailability 30%
|
| gptkbp:formulation |
tablet
|
| gptkbp:future_plans |
commercialized
|
| gptkbp:has |
240 mg daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neratinib
|
| gptkbp:interactsWith |
CYP2D6
CYP3A4 |
| gptkbp:isATypeOf |
698387-09-6
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:mandates |
HER2-positive breast cancer
|
| gptkbp:marketedAs |
gptkb:Nerlynx
|
| gptkbp:operates_in |
L01XX32
|
| gptkbp:patentExpiration |
2024
|
| gptkbp:releaseYear |
2004
2017 |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
nausea vomiting diarrhea rash |
| gptkbp:targets |
HER2
|
| gptkbp:triggerType |
tyrosine kinase inhibitor
|
| gptkbp:usedFor |
breast cancer
|